Lilly set to offer doses of Zepbound single-dose vials through its LillyDirect Self Pay Pharmacy Solutions platform

Eli Lilly has recently announced that the highest approved doses of Zepbound 12.5 mg and 15 mg will soon be available in single-dose vials for $499 per month through LillyDirect’s Self Pay Pharmacy Solutions and the Zepbound Self Pay Journey Program. This allows health care providers to begin prescribing the 12.5 mg and 15 mg vials on July 7, and shipments to patients will begin in early August. With the addition of these doses, every strength of Zepbound vial will be available for $499/month or less to any eligible adult with obesity and a valid prescription, regardless of insurance.

“Obesity is a serious, chronic disease, and access to obesity medications should be treated with the same urgency as other chronic conditions,” said Rhonda Pacheco, group vice president of U.S. Cardiometabolic Health at Lilly. “Lilly was the first company to offer a self-pay solution for an FDA-approved obesity medication, and we continue to work to expand coverage for Zepbound. In the meantime, the availability of the two highest-dose Zepbound vials gives providers and patients another important treatment option.”

Note that Zepbound is also available in 2.5 mg, 5 mg, 7.5 mg, 10 mg, 12.5 mg, or 15 mg per 0.5 mL doses in a single-dose pen. The 2.5 mg is a starting dose and not an approved maintenance dose. The recommended maintenance doses are 5 mg, 10 mg, or 15 mg injected subcutaneously once per week for weight reduction and long-term maintenance. The recommended maintenance doses are 10 mg or 15 mg for OSA.

---

---

Related Topics and Keywords

dual GLP-1/GIP receptor agonist CT-388, Eli Lilly, Lilly's tirzepatide, Zepbound™